The relationship between external beam radiotherapy dose and chronic urinary dysfunction - A methodological critique

Radiotherapy and Oncology

Volumn 97, Issue 1, 2010, Pages 40-47

  Rosewall, Tara ^a,b   Catton, Charles ^a   Currie, Geoffrey ^b   Bayley, Andrew ^a   Chung, Peter ^a   Wheat, Janelle ^b   Milosevic, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Bladder; Dose constraints; Dose volume histograms; Intensity modulated radiotherapy; Radiation induced effects; Toxicity

Indexed keywords

DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; URINARY DYSFUNCTION; URINARY TRACT;

CHRONIC DISEASE; HUMANS; NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; URINARY TRACT; UROLOGIC DISEASES;

EID: 77957876501     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.08.002     Document Type: Review

References (107)

1. G.N. Antonakopoulos, R.M. Hicks, and R.J. Berry The subcellular basis of damage to the human urinary bladder induced by irradiation J Pathol 143 1984 103 116
2. N. Einhorn, C. Trope, and M. Ridderheim A systematic overview of radiation therapy effects in cervical cancer (cervix uteri) Acta Oncol 42 2003 546 556 (Pubitemid 37193843)
3. S. Nilsson, B.J. Norlen, and A. Widmark A systematic overview of radiation therapy effects in prostate cancer Acta Oncol 43 2004 316 381
4. N. Einhorn, C. Trope, and M. Ridderheim A systematic overview of radiation therapy effects in uterine cancer (corpus uteri) Acta Oncol 42 2003 557 561 (Pubitemid 37193844)
5. B. Glimelius, H. Gronberg, and J. Jarhult A systematic overview of radiation therapy effects in rectal cancer Acta Oncol 42 2003 476 492 (Pubitemid 37193839)
6. L. Henningsohn, H. Wijkstrom, and P.W. Dickman Distressful symptoms after radical radiotherapy for urinary bladder cancer Radiother Oncol 62 2002 215 225
7. C.C. Ling, G.J. Kutcher, and R. Mohan Understanding radiation damage in late effect normal tissues: learning to negotiate the dose-volume-complication terrain or waiting for Godot? Int J Radiat Oncol Biol Phys 31 1995 1357 1360
8. S.M. Bentzen High-tech in radiation oncology: should there be a ceiling? Int J Radiat Oncol Biol Phys 58 2004 320 330
9. C. Vargas, A. Martinez, and L.L. Kestin Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy Int J Radiat Oncol Biol Phys 62 2005 1297 1308
10. D. Vordermark, M. Schwab, and R. Ness-Dourdoumas Association of anorectal dose-volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate Radiother Oncol 69 2003 209 214
11. C. Greco, C. Mazzetta, and F. Cattani Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer Radiother Oncol 69 2003 215 222
12. C. Fiorino, C. Cozzarini, and V. Vavassori Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions Radiother Oncol 64 2002 1 12
13. M.J. Zelefsky, Z. Fuks, and M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876 881 (Pubitemid 32750970)
14. C. Fiorino, T. Rancati, and R. Valdagni Predictive models of toxicity in external radiotherapy: dosimetric issues Cancer 115 2009 3135 3140
15. C. Fiorino, R. Valdagni, and T. Rancati Dose-volume effects for normal tissues in external radiotherapy: Pelvis Radiother Oncol 93 2009 153 167
16. R. Valdagni, T. Rancati, and C. Fiorino Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues Cancer 115 2009 3141 3149
17. M.J. Chen, E. Weltman, and R.M. Hanriot Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity? Radiat Oncol 2 2007 6
18. M.R. Cheung, S.L. Tucker, and L. Dong Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1059 1065
19. D.P. Dearnaley, E. Hall, and D. Lawrence Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects Br J Cancer 92 2005 488 498
20. A. Harsolia, C. Vargas, and D. Yan Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study Int J Radiat Oncol Biol Phys 69 2007 1100 1109
21. S.A. Mangar, K. Foo, and A. Norman Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer Clin Oncol (R Coll Radiol) 18 2006 466 473
22. J.M. Michalski, J.A. Purdy, and K. Winter Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406 Int J Radiat Oncol Biol Phys 46 2000 391 402
23. S.T. Peeters, W.D. Heemsbergen, and W.L. van Putten Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy Int J Radiat Oncol Biol Phys 61 2005 1019 1034
24. M. Pinkawa, K. Fischedick, and B. Asadpour Low-grade toxicity after conformal radiation therapy for prostate cancer - impact of bladder volume Int J Radiat Oncol Biol Phys 64 2006 835 841
25. D. Brabbins, A. Martinez, and D. Yan A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity Int J Radiat Oncol Biol Phys 61 2005 400 408 (Pubitemid 40164433)
26. A.B. Jani, C.M. Hand, and C.A. Pelizzari Biological-effective versus conventional dose volume histograms correlated with late genitourinary, gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis BMC Cancer 3 2003 16
27. P.C. Koper, P. Jansen, and W. van Putten Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial Radiother Oncol 73 2004 1 9
28. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the m. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
29. J.M. Michalski, K. Winter, and J.A. Purdy Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V Int J Radiat Oncol Biol Phys 62 2005 706 713
30. J.M. Michalski, K. Winter, and J.A. Purdy Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406 Semin Radiat Oncol 12 2002 75 80 (Pubitemid 34246073)
31. J.M. Michalski, K. Winter, and J.A. Purdy Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II Int J Radiat Oncol Biol Phys 56 2003 192 198
32. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
33. J.K. Ryu, K. Winter, and J.M. Michalski Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) Int J Radiat Oncol Biol Phys 54 2002 1036 1046
34. M. Skala, T. Rosewall, and L. Dawson Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 68 2007 690 698
35. M.R. Storey, A. Pollack, and G. Zagars Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial Int J Radiat Oncol Biol Phys 48 2000 635 642
36. R.K. Valicenti, K. Winter, and J.D. Cox RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys 57 2003 614 620
37. M.J. Zelefsky, Z. Fuks, and M. Hunt High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 53 2002 1111 1116
38. S.M. Bentzen, and J. Overgaard Patient-to-patient variability in the expression of radiation-induced normal tissue injury Semin Radiat Oncol 4 1994 68 80
39. M.T. Milano, L.S. Constine, and P. Okunieff Normal tissue tolerance dose metrics for radiation therapy of major organs Semin Radiat Oncol 17 2007 131 140
40. I. Turesson, J. Nyman, and E. Holmberg Prognostic factors for acute and late skin reactions in radiotherapy patients Int J Radiat Oncol Biol Phys 36 1996 1065 1075
41. M. Roach 3rd Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer Urol Clin North Am 31 2004 353 366
42. C.N. Andreassen, J. Alsner, and J. Overgaard Does variability in normal tissue reactions after radiotherapy have a genetic basis - where and how to look for it? Radiother Oncol 64 2002 131 140
43. E.L. Travis Genetic susceptibility to late normal tissue injury Semin Radiat Oncol 17 2007 149 155
44. S.M. Bentzen Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology Nat Rev Cancer 6 2006 702 713
45. A.A. Martinez, D. Yan, and D. Lockman Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer Int J Radiat Oncol Biol Phys 50 2001 1226 1234
46. S.H. Huang, C. Catton, and J. Jezioranski The effect of changing technique, dose, and PTV margin on therapeutic ratio during prostate radiotherapy Int J Radiat Oncol Biol Phys 71 2008 1057 1064
47. F.M. Kong, C. Pan, and A. Eisbruch Physical models and simpler dosimetric descriptors of radiation late toxicity Semin Radiat Oncol 17 2007 108 120
48. A. Jackson, E.D. Yorke, and K. Rosenzweig The atlas of complication incidence. A proposal for a new sandard for reporting the results of radiotherapy protocols Semin Radiat Oncol 16 2006 260 268
49. M. Pinkawa, B. Asadpour, and B. Gagel Prostate position variability and dose-volume histograms in radiotherapy for prostate cancer with full and empty bladder Int J Radiat Oncol Biol Phys 64 2006 856 861
50. R.E. Drzymala, R. Mohan, and L. Brewster Dose-volume histograms Int J Radiat Oncol Biol Phys 21 1991 71 78
51. J.Y. Ting, X. Wu, and J.A. Fiedler Dose-volume histograms for bladder and rectum Int J Radiat Oncol Biol Phys 38 1997 1105 1111
52. E. Berthelet, M. Liu, and P. Truong CT slice index and thickness: impact on organ contouring in radiation treatment planning for prostate cancer J Appl Clin Med Phys 4 2003 365 373
53. A. Shirkhoda Lower urinary tract, normal anatomy with CT and MRI correlations 1st ed. A. Shirkhoda, B. Madrazo, Pelvic ultrasound vol. 1 1992 Lippincott Williams & Wilkins 1 17
54. H. Gray The urinary bladder 20th ed. W.H. Lewis, Anatomy of the human body vol. 1 1918 Lea & Febiger Philadelphia 1396
55. M.F. Milosevic, and M.K. Gospodarowicz The urinary bladder J. Cox, K. Ang, 9th ed. Radiation oncology: rationale, technique, results vol. 1 2007 Mosby
56. J.C. Roeske, J.D. Forman, and C.F. Mesina Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy Int J Radiat Oncol Biol Phys 33 1995 1321 1329
57. M. van Herk, A. Bruce, and A.P. Kroes Quantification of organ motion during conformal radiotherapy of the prostate by three dimensional image registration Int J Radiat Oncol Biol Phys 33 1995 1311 1320
58. D. Yan, D.A. Jaffray, and J.W. Wong A model to accumulate fractionated dose in a deforming organ Int J Radiat Oncol Biol Phys 44 1999 665 675
59. J.V. Lebesque, A.M. Bruce, and A.P. Kroes Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer Int J Radiat Oncol Biol Phys 33 1995 1109 1119
60. M.R. Stam, E.N. van Lin, and L.P. van der Vight Bladder filling variation during radiation treatment of prostate cancer: can the use of a bladder ultrasound scanner and biofeedback optimize bladder filling? Int J Radiat Oncol Biol Phys 65 2006 371 377
61. S.A. Mangar, E. Scurr, and R.A. Huddart Assessing intra-fractional bladder motion using cine-MRI as initial methodology for predictive organ localization (POLO) in radiotherapy for bladder cancer Radiother Oncol 85 2007 207 214
62. L.J. Verhey Immobilizing and positioning patients for radiotherapy Semin Radiat Oncol 5 1995 100 114
63. V. Rudat, P. Schraube, and D. Oetzel Combined error of patient positioning variability and prostate motion uncertainty in 3D conformal radiotherapy of localized prostate cancer Int J Radiat Oncol Biol Phys 35 1996 1027 1034
64. V. Landoni, B. Saracino, and S. Marzi A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRT Int J Radiat Oncol Biol Phys 65 2006 587 594
65. P.A. Kupelian, K.M. Langen, and O.A. Zeidan Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 66 2006 876 882
66. T.R. Mackie, J. Kapatoes, and K. Ruchala Image guidance for precise conformal radiotherapy Int J Radiat Oncol Biol Phys 56 2003 89 105
67. B. Schaly, G.S. Bauman, and W. Song Dosimetric impact of image-guided 3D conformal radiation therapy of prostate cancer Phys Med Biol 50 2005 3083 3101
68. P. van Haaren, A. Bel, and P. Hofman Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients Radiother Oncol 90 2009 291 298
69. D. Watkins-Bruner, C. Scott, and C. Lawton RTOG's first quality of life study - RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer Int J Radiat Oncol Biol Phys 33 1995 901 906
70. G. Goldner, N. Wachter-Gerstner, and S. Wachter Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. Differences between patient's self-reported questionnaire and the corresponding doctor's report Strahlenther Onkol 179 2003 320 327
71. D.W. Bruner Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials? J Clin Oncol 25 2007 5345 5347
72. D.W. Bruner, C.J. Bryan, and N. Aaronson Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks J Clin Oncol 25 2007 5051 5057
73. E. Basch, A. Iasonos, and T. McDonough Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study Lancet Oncol 7 2006 903 909
74. M.D. Brundage, J.L. Pater, and B. Zee Assessing the reliability of two toxicity scales: implications for interpreting toxicity data J Natl Cancer Inst 85 1993 1138 1148
75. T. Rosewall, J. Yan, and A. Bayley Inter-professional variability in the assignment and recording of acute toxicity grade using the RTOG system during prostate radiotherapy Radiother Oncol 90 2009 395 399
76. E. Basch, D. Artz, and D. Dulko Patient online self-reporting of toxicity symptoms during chemotherapy J Clin Oncol 23 2005 3552 3561
77. C.B. Scott, and T.F. Pajak LENT: a good beginning but Int J Radiat Oncol Biol Phys 31 1995 1347 1348
78. I.J. Korfage, T. Hak, and H.J. de Koning Patients' perceptions of the side-effects of prostate cancer treatment - a qualitative interview study Soc Sci Med 63 2006 911 919
79. F.J. Fowler Jr., M.J. Barry, and G. Lu-Yao Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience. 1988-1990 (updated June 1993) Urology 42 1993 622 629
80. M.J. Zelefsky, D. Cowen, and Z. Fuks Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma Cancer 85 1999 2460 2468
81. L. Peeters, H. Withers, and B. Brown Complicating issues in complication reporting Int J Radiat Oncol Biol Phys 31 1995 1349 1351
82. S.M. Bentzen, W. Dorr, and M.S. Anscher Normal tissue effects: reporting and analysis Semin Radiat Oncol 13 2003 189 202
83. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
84. L.B. Marks, P.R. Carroll, and T.C. Dugan The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy Int J Radiat Oncol Biol Phys 31 1995 1257 1280
85. V. Fonteyne, G. Villeirs, and N. Lumen Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer Radiother Oncol 92 2009 42 47
86. L.B. Marks, and J. Ma Challenges in the clinical application of advanced technologies to reduce radiation-associated normal tissue injury Int J Radiat Oncol Biol Phys 69 2007 4 12
87. E.L. Travis Organizational response of normal tissues to irradiation Semin Radiat Oncol 11 2001 184 196
88. W.D. Heemsbergen, A. Al-Mamgani, and M.G. Witte Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs 78 Gy): relationships with local dose, acute effects, and baseline characteristics Int J Radiat Oncol Biol Phys 2010 [E-Pub, Ahead of Print]
89. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500
90. B.D. Ross, T.L. Chenevert, and A. Rehemtulla Magnetic resonance imaging in cancer research Eur J Cancer 38 2002 2147 2156
91. J. Hickey, and F. Goldberg Urinary bladder and ureters Ultrasound review of the abdomen, male pelvis & small parts vol. 1 1999 Philadelphia Lippincott 253 262
92. A.C. Perkins, H.M. Price, and D.J. Cox Ultrasound in the localisation of bladder tumours for radiotherapy treatment planning Br J Radiol 57 1984 241 245
93. N. Burridge, A. Amer, and T. Marchant Online adaptive radiotherapy of the bladder: small bowel irradiated-volume reduction Int J Radiat Oncol Biol Phys 66 2006 892 897
94. W.A. Tome, S.L. Meeks, and N.P. Orton Commissioning and quality assurance of an optically guided three-dimensional ultrasound target localization system for radiotherapy Med Phys 29 2002 1781 1788
95. K.K. Brock, M.B. Sharpe, and L.A. Dawson Accuracy of finite element model-based multi-organ deformable image registration Med Phys 32 2005 1647 1659
96. E.M. Charles-Edwards, and N.M. deSouza Diffusion-weighted magnetic resonance imaging and its application to cancer Cancer Imaging 6 2006 135 143
97. E.S. Evans, C.A. Hahn, and Z. Kocak The role of functional imaging in the diagnosis and management of late normal tissue injury Semin Radiat Oncol 17 2007 72 80
98. D.L. Thomas, M.F. Lythgoe, and G.S. Pell The measurement of diffusion and perfusion in biological systems using magnetic resonance imaging Phys Med Biol 45 2000 R97 138
99. D. Landis, K. Wallner, and J. Locke Late urinary function after prostate brachytherapy Brachytherapy 1 2002 21 26
100. S. Mallick, R. Azzouzi, and L. Cormier Urinary morbidity after 125I brachytherapy of the prostate BJU Int 92 2003 555 558
101. M. Pisarska, and S. Sajdak Lower urinary tract function after postoperative radiotherapy in the treatment of cervical cancer Eur J Gynaecol Oncol 24 2003 490 494
102. M. Pisarska, W. Zietkowiak, and A. Sibila Function of the lower urinary tract in patients after treatment of cervical cancer Ginekol Pol 73 2002 919 924 [abstract]
103. G.S. Steele, M.P. Sullivan, and D.J. Sleep Combination of symptom score, flow rate and prostate volume for predicting bladder outflow obstruction in men with lower urinary tract symptoms J Urol 164 2000 344 348
104. Y. Chen, A. Trotti, and C.N. Coleman Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation Int J Radiat Oncol Biol Phys 64 2006 1442 1451
105. P.J. Hauser, M.G. Dozmorov, and B.L. Bane Abnormal expression of differentiation related proteins and proteoglycan core proteins in the urothelium of patients with interstitial cystitis J Urol 179 2008 764 769
106. R.E. Hurst, R.M. Moldwin, and S.G. Mulholland Bladder defense molecules, urothelial differentiation, urinary biomarkers, and interstitial cystitis Urology 69 2007 17 23
107. S.K. Keay, C.O. Zhang, and J. Shoenfelt Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis Urology 57 2001 9 14